Single toe necrosis complicating DFU requires an amputation performed in the operating room by a surgeon (ORAS) . Bedside amputation by a diabetologist (BAD) complying with the surgical rules might be an option in case of disagreement with the surgeon about the amputation level (major favored by the surgeon) and/or an anesthetic contraindication. In our monocentric, retrospective study, we assessed the one year prognosis (healing rate without extra surgery) of a single toe necrosis amputation over DFU performed by a diabetologist or a surgeon. Amputation levels (transphalangeal, TPA, metatarsophalangeal disarticulation, MPD, single transmetatarsal, TMA) were decided by our multidisciplinary team. Out of 7patients admitted with DFU (05.2016-10.2020) , 57 (8%) were included because of single toe necrosis (BAD n=33, 58%; ORAS n=24, 42%) . Amputation levels TPA, MPD, TMA were respectively 26, 47, 27%. The median duration of follow-up was 28 months. Patients characteristics were non statistically different between groups except for the dorsal arch permeability: males 74%; median age 64y; Type 2 Diabetes Mellitus (DM) 97%; median DM duration 17y. The rate of permeable dorsal arch was significantly lower in the BAD group (45% vs. 75%, p=0.03) . Single TMA rate was significantly higher in the ORAS group (50% vs. 9%, p=0.001) . The one year healing rate without extra surgery was statistically different between the two groups (BAD 58% vs. ORAS 83%, p=0.05) . The need for extra surgery was significantly higher in the BAD group (42% vs. ORAS 13%, p=0.02) . The overall mortality was non significantly different between groups (BAD 21% vs. ORAS 4%, p=0.12) . For a single toe necrosis over DFU, in patients with a high risk for a circumscribed toe amputation failure as stated by the surgeon, the results of bedside amputation performed by a diabetologist invalidated this unfavorable prognosis in most cases.


F.Féron: None. J.Riveline: None. J.Gautier: Other Relationship; Novo Nordisk, Sanofi, Speaker's Bureau; Eli Lilly and Company. J.Kevorkian: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at